Abstract Book

CL 10: Prostate........................................................................................................ (Abs. 499-505) PH 9: Analysis of treatment outcomes......................................................................... (Abs. 506-512) PH 10: Treatment planning 2...................................................................................... (Abs. 513-519) RTT 5: Motion management and adative stratgies. ........................................................ (Abs. 520-526) Poster Viewing Poster viewing 10: Images and analyses...................................................................... (Abs. 527-535) Randomised Trials Selected randomised trials......................................................................................... (Abs. 536-538) Award Lecture Klaas Breur Award Lecture............................................................................................... (Abs. 539) Symposium Challenges in human resources in radiotherapy............................................................. (Abs. 540-543) Joint Symposium ESTRO-ESR: New imaging approaches for radiotherapy.................................................. (Abs. 544-547) Symposium Biomarker driven hypoxic modification......................................................................... (Abs. 548-550) Debate This house believes that treatment intensification in stage III is a dream rather than a reality?................................................................................................ (Abs. 551-552) Symposium What’s new in the management of high risk prostate cancer patients in 2018?. ................. (Abs. 553-555) Outcome prediction models for RT indications - development, validation, acceptance, commissioning and application................................................................................... (Abs. 556-558) Debate Is there still a place for patient specific QA?. ................................................................ (Abs. 559-560) Symposium Focus on site - BREAST. ............................................................................................ (Abs. 561-563) Poster Viewing Poster viewing 11: Emerging technologies: radiobiology and physics hand in hand............. (Abs. 564-572) Symposium Planning future global radiotherapy services................................................................. (Abs. 573-575) Normal tissue dose-response modelling across radiation modalities.................................. (Abs. 576-579) Proffered Papers RB 6: Role and impact of Normal tissue RT response biology........................................... (Abs. 580-586) CL 11: CNS. ............................................................................................................ (Abs. 587-593) CL 12: Late-breaking abstracts and practice changing trials............................................ (Abs. 594-600) PH 11: Emerging technologies.................................................................................... (Abs. 601-607) PH 12: Audits and QA. .............................................................................................. (Abs. 608-614) RTT 6: Treatment planning and quality assurance.......................................................... (Abs. 615-620) Poster Viewing Poster viewing 12: Prostate. ...................................................................................... (Abs. 621-629) Award Lecture Jens Overgaard Legacy Award.......................................................................................... (Abs. 630) Academic award: Jack Fowler University of Wisconsin Award................................................. (Abs. 631) Company Award Lectures. ......................................................................................... (Abs. 632-633)

TUESDAY 24 APRIL 2018

Teaching Lecture Navigation in the publication ethics landscape: Publish or perish or...?.................................... (Abs. 634) Risk Management: Quality and Safety New EU legislation and implementation......................... (Abs. 635) Normal tissue stem cells and cancer stem cells in radiation response. .................................... (Abs. 636) Hypofractionated external beam radiotherapy for Prostate cancer: what have we learned in the last 15 years?........................................................................ (Abs. 637) State of the art in treatment of oesophageal cancer............................................................. (Abs. 638) MRI based radiotherapy – What can go wrong and how to QA?.............................................. (Abs. 639) Photon dosimetry protocols: what is new?.......................................................................... (Abs. 640)